通过同化方法制备的带有exenatide的PLGA微球的配方和特征
Cameron White1, Steven P Schwendeman2,3
1Department of Pharmaceutical Sciences, Biointerfaces Institute, University of Michigan, Ann Arbor, MI, 48109, USA.
Drug delivery and translational research
|December 9, 2025
概括
研究人员通过协优化了exenatide酸盐在多聚乳-co-glycolide (PLGA) 微球中的微封装. 这项研究为开发具有控制释放的长效注射性配方建立了框架.
科学领域:
- 生物材料科学 生物材料科学
- 制药技术 制药技术 制药技术
- 药物输送系统 药物输送系统
背景情况:
- 拜杜®利用聚乳酸-协同甘油酸 (PLGA) 微球来持续释放GLP-1受体激活剂,即外酸.
- 配方变量的确切影响PLGA微球属性和exenatide封装仍然不完全理解.
- 优化微封装过程对于开发有效的长效注射疗法至关重要.
研究的目的:
- 为了研究关键配方参数对PLGA微球中的exenatide乙酸封装的影响.
- 为具有类似于Bydureon®的特征的PLGA微球建立稳定的制造条件.
- 开发一个框架,用于微封装的使用同化.
主要方法:
- 通过单一乳液方法采用同化 (相分离) 方法来制备PLGA微球.
- 选过程变量包括PLGA度,溶剂比率 (DCM:水,DCM:Si油) 和保留时间.
- 评估了配方产量,残留溶剂,封装效率和体外释放概况 (24小时爆发和56天释放).
主要成果:
- 6%的PLGA度和1分钟的保留时间被确定为最佳参数.
- 配方在24小时内实现了高产量 (>50%) 和低初始爆发释放 (2-6%).
- 微球显示在56天内持续的体外释放,与商业产品一致.
结论:
- 通过同化建立了PLGA微球配方的强大框架,通过同化建立了exenatide酸盐.
- 优化的工艺产生了具有理想封装效率和受控释放配置文件的微球.
- 这些发现适用于开发通用和新型微封装.
相关概念视频
01:28Factors Influencing Drug Absorption: Pharmaceutical Parameters
372
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
372
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
174
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
174
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
127
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
127
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
262
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
262
01:27Bioavailability Enhancement: Drug Permeability Enhancement
163
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
163